Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: Emergence of the Solution to an Important Unmet Need.
Alzheimer's Disease (AD) represents an increasing problem as the overall population ages. The identification of reliable biomarkers of AD has, therefore, become increasingly important. This is not only for risk prediction and diagnosis in order to provide appropriate care, but also to identify those patients at high risk of AD development who may be eligible for inclusion in clinical trials of novel therapies. Treatment in the early stages of the disease are urgently needed, as these are expected to yield the greatest benefits. The cerebrospinal fluid biomarkers amyloid beta (1-42), hyperphosphorylated Tau and total Tau have been most extensively evaluated. Their combination has been shown to be valuable in identifying AD patients, including those who will progress to AD among a wider group of subjects with only subjective memory complaints or in very early disease stages. While commercially available diagnostic tests for these biomarkers are available, implementation in clinical practice is associated with a number of problems, such as absorption of amyloid beta (1-42) to laboratory tubes, a high degree of batch-to-batch variation with the current test, and the lack of certified reference material. Therefore, there is a need for increased automation and implementation on routine diagnostic platforms in order to support the cost-effective and reliable introduction of the tests on a wider scale. As the use of these biomarkers in research and in clinical practice continues to expand, extensive standardisation efforts are being put in place to address the challenges associated with the use of these biomarkers. Together with the development of additional biomarkers for early and differential diagnosis, this casts good foresight to serve the needs of an increasing patient population.
Neurochemistry Laboratory and Biobank , Dept. of Clinical Chemistry, Neuroscience Campus Amsterdam, VU University Medical Center Amsterdam.
C E
CE
Teunissen
Neurochemistry Laboratory and Biobank , Dept. of Clinical Chemistry, Neuroscience Campus Amsterdam, VU University Medical Center Amsterdam.
Eaj
E
Willemse
Abeta(1–42); Alzheimer’s disease; Tau; biobanking; biomarker; cerebrospinal fluid; standardisation
Nat Genet. 2011 May;43(5):436-41
21460841
J Neurosci. 2010 May 5;30(18):6367-74
20445063
Alzheimers Dement. 2013 May;9(3):251-61
23622690
PLoS One. 2012;7(2):e31084
22328928
Neurology. 1999 May 12;52(8):1555-62
10331678
Int J Biochem Cell Biol. 2012 Nov;44(11):2085-93
22903022
Curr Psychiatry Rep. 2011 Dec;13(6):437-42
22052382
Clin Chem. 2010 Feb;56(2):248-53
19833838
Clin Chem. 2013 Aug;59(8):1187-94
23592508
Neurology. 2013 Nov 12;81(20):1753-8
24132375
J Neurol Sci. 1998 Jun 30;158(2):134-40
9702683
Lancet Neurol. 2010 Jan;9(1):119-28
20083042
Science. 1998 Jan 9;279(5348):242-7
9422699
Science. 2002 Oct 25;298(5594):789-91
12399581
Neurology. 2012 Jan 3;78(1):47-54
22170879
Nat Rev Neurol. 2010 Mar;6(3):131-44
20157306
J Biol Chem. 2012 Mar 9;287(11):8154-62
22267726
Lancet Neurol. 2006 Mar;5(3):228-34
16488378
Neurology. 2012 Feb 14;78(7):468-76
22302554
J Alzheimers Dis. 2012;31(2):335-41
22531418
J Neural Transm (Vienna). 2009 Feb;116(2):203-12
19142572
Nat Neurosci. 2013 Sep;16(9):1299-305
23933749
Ann Neurol. 1995 Oct;38(4):643-8
7574461
Nat Genet. 2011 May;43(5):429-35
21460840
J Alzheimers Dis. 2012;31(1):13-20
22495345
Neurobiol Aging. 1997 Jul-Aug;18(4):351-7
9330961
Int J Alzheimers Dis. 2010 Sep 27;2010:null
20936143
Neurosci Lett. 2001 Jan 19;297(3):187-90
11137759
Neurobiol Aging. 2012 Aug;33(8):1591-8
21741127
Alzheimers Dement. 2013 Sep;9(5):481-7
23232269
Science. 1990 Jun 1;248(4959):1058-60
2111582
J Alzheimers Dis. 2012;29(1):229-38
22232006
Alzheimers Dement. 2011 Jul;7(4):386-395.e6
21784349
Resuscitation. 2014 Feb;85(2):227-32
24231570
J Alzheimers Dis. 2013;33(3):807-22
23034521
JAMA. 2009 Jul 22;302(4):385-93
19622817
Lancet Neurol. 2013 Jun;12(6):609-22
23684085
J Neurosci. 2011 Nov 16;31(46):16507-16
22090477
Immun Ageing. 2013 May 11;10(1):18
23663286
Lancet Neurol. 2013 Feb;12(2):207-16
23332364
N Engl J Med. 2012 Aug 30;367(9):795-804
22784036
Neurodegener Dis. 2012;10(1-4):138-40
22302034
J Neurol. 2004 Jul;251(7):870-6
15258792